SUCCESSFUL TREATMENT OF AN NTRK-FUSION POSITIVE INFANTILE GLIOBLASTOMA WITH LAROTRECTINIB, A TARGETED TRK INHIBITOR

被引：4
|
作者：
Buerki, Robin [1 ]
Banerjee, Anuradha [1 ,2 ]
Zamorski, Alexandra [3 ]
Cox, Michael [3 ]
Raber, Shannon [4 ]
Solomon, David [5 ]
Mueller, Sabine [6 ]
机构：
[1] Univ Calif San Francisco, Dept Neurol Surg, San Francisco, CA 94143 USA
[2] Univ Calif San Francisco, Dept Pediat, San Francisco, CA 94143 USA
[3] Loxo Oncol Inc, Clin Dev, San Francisco, CA USA
[4] Univ Calif San Francisco, Dept Pediat Hematol Oncol, San Francisco, CA 94143 USA
[5] Univ Calif San Francisco, Dept Pathol, San Francisco, CA 94143 USA
[6] Univ Calif San Francisco, Dept Neurol Surg, San Francisco, CA 94143 USA
来源：
NEURO-ONCOLOGY | 2019年 / 21卷
关键词：
D O I：
10.1093/neuonc/noz036.109
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
HGG-15
引用
收藏
页码：89 / 90
页数：2
相关论文
共 50 条
  • [1] Potential role of larotrectinib (LOXO-101), a selective pan-TRK inhibitor, in NTRK fusion-positive recurrent glioblastoma
    Schram, Alison M.
    Taylor, Barry S.
    Hechtman, Jaclyn F.
    Benayed, Ryma
    Wang, Lu
    Hanusch, Bethany
    Young, Robert
    Grommes, Christian
    Ku, Nora
    Hyman, David M.
    Kaley, Thomas
    Drilon, Alexander
    CANCER RESEARCH, 2017, 77
  • [2] Improving Outcomes in Pediatric NTRK Gene Fusion-Positive Solid Tumors: Importance of Genomic Testing and Targeted Therapy With the TRK Inhibitor Larotrectinib
    Laetsch, Theodore W.
    CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2024, 22 (04)
  • [3] A newborn with a large NTRK fusion positive infantile fibrosarcoma successfully treated with larotrectinib
    Caldwell, Kenneth J.
    De La Cuesta, Esther
    Morin, Cara
    Pappo, Alberto
    Helmig, Sara
    PEDIATRIC BLOOD & CANCER, 2020, 67 (09)
  • [4] Successful treatment of lipofibromatosis-like neural tumor of the lumbar spine with an NTRK-fusion inhibitor
    Dupuis, Megan
    Shen, Yulei
    Curcio, Christian
    Meis, Jeanne M.
    Wang, Wei-Lien
    Amini, Behrang
    Rhines, Laurence
    Reuther, Jacquelyn
    Roy, Angshumoy
    Fisher, Kevin E.
    Conley, Anthony P.
    Livingston, J. Andrew
    CLINICAL SARCOMA RESEARCH, 2020, 10 (01)
  • [5] NTRK fusion-positive cancers and TRK inhibitor therapy
    Emiliano Cocco
    Maurizio Scaltriti
    Alexander Drilon
    Nature Reviews Clinical Oncology, 2018, 15 : 731 - 747
  • [6] NTRK fusion-positive cancers and TRK inhibitor therapy
    Cocco, Emiliano
    Scaltriti, Maurizio
    Drilon, Alexander
    NATURE REVIEWS CLINICAL ONCOLOGY, 2018, 15 (12) : 731 - 747
  • [7] Comment on: A newborn with a large NTRK fusion positive infantile fibrosarcoma successfully treated with larotrectinib
    Slomovic, Alana
    Amaral, Terry
    Lobko, Igor
    Siegel, David N.
    Goldfisher, Rachelle
    Kessel, Rachel
    Levy, Carolyn Fein
    PEDIATRIC BLOOD & CANCER, 2021, 68 (06)
  • [8] TARGETED THERAPY Larotrectinib effective against TRK-fusion-positive cancers
    Sidaway, Peter
    NATURE REVIEWS CLINICAL ONCOLOGY, 2018, 15 (05) : 264 - 264
  • [9] Larotrectinib in TRK fusion-positive cancers
    Burki, Talha Khan
    LANCET ONCOLOGY, 2018, 19 (04): : E187 - E187
  • [10] NTRK Fusion-Positive Congenital Spinal Glioblastoma treated with Carboplatin, Etoposide, and Larotrectinib
    Vallis, Graham
    PEDIATRICS, 2021, 147 (03)
12345